CRIS Current Research Information System

FINELLI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.336
AS - Asia 2.740
EU - Europa 2.452
AF - Africa 317
SA - Sud America 123
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 4
Totale 8.987
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.297
SG - Singapore 845
VN - Vietnam 706
CN - Cina 650
GB - Regno Unito 646
IT - Italia 410
SE - Svezia 355
DE - Germania 315
HK - Hong Kong 175
FR - Francia 146
RU - Federazione Russa 132
IN - India 128
JP - Giappone 94
TG - Togo 92
BR - Brasile 89
IE - Irlanda 83
SC - Seychelles 73
NL - Olanda 61
ZA - Sudafrica 61
EE - Estonia 52
FI - Finlandia 44
NG - Nigeria 42
UA - Ucraina 38
CI - Costa d'Avorio 36
HR - Croazia 35
CA - Canada 28
BG - Bulgaria 27
BE - Belgio 25
JO - Giordania 23
AT - Austria 22
CH - Svizzera 20
AR - Argentina 16
EU - Europa 15
BD - Bangladesh 14
PL - Polonia 12
PK - Pakistan 10
TH - Thailandia 10
TR - Turchia 10
ID - Indonesia 9
UZ - Uzbekistan 9
KR - Corea 7
MX - Messico 7
PH - Filippine 7
IQ - Iraq 6
SA - Arabia Saudita 6
EC - Ecuador 5
ES - Italia 5
IR - Iran 5
LB - Libano 5
TW - Taiwan 5
CO - Colombia 4
GR - Grecia 4
IL - Israele 4
KE - Kenya 4
RO - Romania 4
VE - Venezuela 4
AU - Australia 3
LT - Lituania 3
MY - Malesia 3
PY - Paraguay 3
AL - Albania 2
CZ - Repubblica Ceca 2
EG - Egitto 2
LV - Lettonia 2
MA - Marocco 2
OM - Oman 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GI - Gibilterra 1
GP - Guadalupe 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
RW - Ruanda 1
Totale 8.987
Salva come PNG Salva come JPEG
Città #
Southend 590
Singapore 588
Ashburn 380
Fairfield 306
Chandler 300
Santa Clara 221
Houston 192
Hong Kong 168
Ann Arbor 156
Bologna 146
Wilmington 142
Seattle 137
Woodbridge 130
San Jose 123
Ho Chi Minh City 116
Princeton 115
Beijing 102
Cambridge 101
Hanoi 100
Lomé 92
Dong Ket 82
Dublin 81
Boardman 78
Padova 59
Tokyo 56
Westminster 55
Nanjing 54
Lauterbourg 48
Abeokuta 41
Abidjan 36
Helsinki 36
Shenyang 36
Jinan 35
New York 35
Milan 34
Redwood City 34
Saint Petersburg 34
Changsha 32
Medford 32
Berlin 27
Los Angeles 27
Sofia 27
Brussels 25
Nanchang 24
Amman 23
Buffalo 23
Hebei 23
Frankfurt am Main 22
Redondo Beach 22
Turin 22
Shanghai 20
Guangzhou 19
Dallas 17
Vienna 16
Bern 15
San Diego 15
Da Nang 14
Jiaxing 14
Munich 14
Falls Church 13
Haiphong 13
Hangzhou 12
Menlo Park 12
Amsterdam 11
Norwalk 11
Tianjin 11
Bremen 10
Montreal 10
Rome 10
São Paulo 10
Tappahannock 10
Toronto 10
Warsaw 10
Yubileyny 10
Dearborn 9
Orem 9
The Dalles 9
Zhengzhou 9
Florence 8
Haikou 8
Hải Dương 8
Jacksonville 8
Turku 8
Valsamoggia 8
Biên Hòa 7
London 7
Bühl 6
Lanzhou 6
Mountain View 6
Phoenix 6
Taizhou 6
Andover 5
Baghdad 5
Brooklyn 5
Can Tho 5
Chennai 5
Chicago 5
Hefei 5
Istanbul 5
Johannesburg 5
Totale 5.848
Salva come PNG Salva come JPEG
Nome #
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 279
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 252
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 226
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 222
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 221
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 219
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 217
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 215
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 213
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 205
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 203
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 200
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 197
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 196
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 186
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 178
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 177
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 173
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 172
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 171
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 165
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 161
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 160
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 159
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 159
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 157
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 155
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 152
Nuclear inositide signaling in myelodysplastic syndromes. 151
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 146
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 146
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 144
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 141
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 139
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 137
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 137
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 137
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 128
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 125
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 125
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 123
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 122
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 121
Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. 119
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 118
Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients 115
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 112
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. 112
null 103
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 103
PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES 82
null 72
null 71
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 67
IS PI-PLC 1 EXPRESSION A RELIABLE PREDICTOR OF RESPONSE IN LOW RISK MDS PATIENTS TREATED WITH LOW-DOSE AZACITIDINE? RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY 65
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 45
null 43
null 41
Totale 9.159
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.517
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.517
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021394 0 0 0 0 0 0 0 0 0 31 27 336
2021/20221.128 121 16 57 97 98 72 36 49 39 150 177 216
2022/20231.301 100 176 77 181 116 96 59 118 206 13 100 59
2023/2024411 21 58 33 36 51 71 14 15 26 55 13 18
2024/20251.120 47 145 86 76 283 77 78 38 11 56 23 200
2025/20262.265 182 218 194 120 338 171 327 86 465 164 0 0
Totale 9.159